Navigation Links
Santaris Pharma Presents Positive Clinical Data on SPC2996 in,Chronic Lymphocytic Leukaemia

r cell death and removal without resorting to chemotherapy.

About SPC2966

SPC2996 is the first of a portfolio of novel experimental drugs blocking harmful gene expression being designed and developed by Santaris Pharma. The drug belongs to a new class of drugs called RNA Antagonists, proprietary to Santaris Pharma, based on the novel three-dimensional analogue of RNA known as Locked Nucleic Acid (LNA). The drug binds with high potency and specificity to the messenger RNA for Bcl-2 and destroys it within the cell, resulting in a reduction in Bcl-2 protein concentration. SPC2996 is an investigational product which has not yet been approved by any regulatory agency as effective or safe for patient use but the novel agent is currently being evaluated in international Phase I/II studies in human CLL in centres in Denmark, France, UK and the USA.

About Santaris Pharma

Santaris Pharma is a clinical-stage biopharmaceutical company focused on developing a new class of drugs intended to switch off the expression of harmful genes. Called RNA Antagonists, these new drugs are being developed by Santaris and its corporate partners for the treatment of cancer and metabolic disorders. Created in May 2003 and backed by a broad group of leading international life science venture capital investors, Santaris Pharma completed a Euro 40m second round of equity financing in May 2006. In July 2006, the Company entered into a global partnership with Enzon Pharmaceuticals of New Jersey to co-develop and commercialise a series of Santaris RNA Antagonists for improving the treatment of cancer.

Santaris Pharma's RNA Antagonist drug pipeline is based on its unique LNA technology. LNA drugs, with their high potency and biostability, have the potential to transform the field of RNAi medicines, making specific and effective gene silencing a reality in human medicine. If this potential is realised, even in part, it may be possible to design new drugs to treat the u
'"/>




Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Santaris Pharma presents positive preclinical data on SPC2996 at the American Association for Cancer Research
2. Sygnis Pharma AG announces date for presentation of clinical results
3. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
6. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
7. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
8. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
9. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
10. Array BioPharma to Present at the C.E Unterbeg, Towbin Emerging Growth Conference
11. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
Post Your Comments:
(Date:5/23/2013)... 2013  TeamHealth Medical Call Center (THMCC), a ... advice lines, announces its newly formed Clinical Advisory ... administrative leaders, provides clinical expertise to advance THMCC,s ... for hospital clients, physician clients and patients. ... it,s imperative to continuously advance our services and ...
(Date:5/23/2013)... 23, 2013 More than half of women ... from chemotherapy and still have excellent outcomes. To educate ... of the largest sources of online consumer information about ... Facebook page provide recently diagnosed women with information sources, ... chemotherapy. "We anticipate these innovative social media ...
(Date:5/23/2013)... May 23, 2013 Anthem Blue Cross patients ... have required them to obtain their medications by mail ... and Whatley Kallas LLC.  The lawsuit, ... that Blue Cross,s mandatory mail order program announced late ... and privacy. "This settlement brings to a ...
Breaking Medicine Technology:TeamHealth Medical Call Center Forms Clinical Advisory Committee 2Agendia Launches Social Media Campaigns to Help Breast Cancer Patients with Chemotherapy Decisions 2Agendia Launches Social Media Campaigns to Help Breast Cancer Patients with Chemotherapy Decisions 3Blue Cross To Allow HIV/AIDS Patients to "Opt-Out" of Mandatory Mail-Order Rx Drug Program, Announces Consumer Watchdog 2Blue Cross To Allow HIV/AIDS Patients to "Opt-Out" of Mandatory Mail-Order Rx Drug Program, Announces Consumer Watchdog 3
(Date:5/24/2013)... A new discovery at Oregon Health & Science University ... reacts when infected with the highly evasive HIV virus ... been utilizing this unique approach to develop its own ... results in animal studies. This latest research finding will ... the journal Science . , "A major ...
(Date:5/24/2013)... 24, 2013 Residents of San Diego ... camp classes. Fitness expert, and Certified Russian Kettlebell Instructor, ... X Bootcamps in San Diego, California. The classes take ... class times offered. Initial sign-ups are available online ... been teaching Kettlebell for years. The bootcamps being ...
(Date:5/24/2013)... Texas (PRWEB) May 24, 2013 ... range of products used outside the central laboratory, ... by a healthcare practitioner or by consumers. This ... coagulation, fertility and pregnancy, infectious and cardiovascular disease ... areas such as critical care, surgical and emergency ...
(Date:5/24/2013)... schizophrenics? Finding the answer for this is at the centre ... from the Bergen fMRI Group at the University of Bergen ... voices. The way they do this is by studying people ... a mental illness. For a five-year period, the group is ... recent report published in Frontiers in Human Neuroscience ...
(Date:5/24/2013)... Reporter , , THURSDAY, May 23 (HealthDay News) -- Type ... with signs of serious complications seen just a few ... on the latest results, it seems like type 2 ... Chiang, senior vice president of medical affairs and community ... faster, and it appears to be at a more ...
Breaking Medicine News(10 mins):Health News:OHSU research highlights promising strategy to help vaccines outsmart HIV 2Health News:Point of Care Diagnostics Market (POC) Analysis and 5 Year Forecast in New Research Report at ReportsnReports.com 2Health News:Point of Care Diagnostics Market (POC) Analysis and 5 Year Forecast in New Research Report at ReportsnReports.com 3Health News:Help at hand for schizophrenics 2Health News:Type 2 Diabetes Progresses Faster in Kids, Study Finds 2Health News:Type 2 Diabetes Progresses Faster in Kids, Study Finds 3
... New Executive LeadershipKOBE, Japan, March 5 Sysmex ... medical diagnostics instrument manufacturer and laboratory information systems ... Corporate and its subsidiaries in the Americas, Europe ... Obe will return to Sysmex Corporate after a ...
... more than 3,000 women in the U.S. and southern ... a vaginal microbicide gel for preventing HIV infection in ... Retroviruses and Opportunistic Infections (CROI), one 0.5 % dose ... to cells in the genital tract, was 30% effective. ...
... printing superstore was honored for ecommerce expertise when President Michael Del ... version of the highly respected Entrepreneur magazine. , ... ... Del Chiaro for the interview based on his proven success in ...
... To Beaver, Star Jerry MathersJACKSON, Miss., March 5 ... will be stopping in Mississippi the week of March ... to help uninsured and financially-struggling Mississippians access information on ... free. With the unemployment rate in Mississippi (7.8 percent) ...
... Inc. (RPI), a wholly owned subsidiary of Ranbaxy ... received approval from the U.S. Food and Drug ... Hydrochlorothiazide (Quinapril + HCTZ) Tablets, 10mg/12.5mg, 20mg/12.5mg ... was submitted by Ranbaxy, from its Ohm Laboratories ...
... a penile extender every day for six months were able ... to 32% and their erectile function by up to 36%, ... issue of BJU International . , Researchers from San ... now suggesting that this treatment could provide a viable alternative ...
Cached Medicine News:Health News:Sysmex Corporation Announces Organizational Changes 2Health News:Clinical trial finds microbicide promising as HIV prevention method for women 2Health News:My1Stop.com President Michael Del Chiaro Interviewed by Entrepreneur.com for ecommerce Expertise 2Health News:Partnership for Prescription Assistance Prepared to Help Mississippi Workers Hurt by Recession 2Health News:Partnership for Prescription Assistance Prepared to Help Mississippi Workers Hurt by Recession 3Health News:Partnership for Prescription Assistance Prepared to Help Mississippi Workers Hurt by Recession 4Health News:Ranbaxy Secures Final FDA Approval for Quinapril Hydrochloride + Hydrochlorothiazide Tablets 2Health News:Penile extender increased flaccid length by almost a third says independent clinical study 2
... Our slimmest full-featured bronchofiberscope yet. The BF-3C40's ... by 0.2mm from the previous model. It ... Olympus models, thanks to the use of ... enlarge the image size by 70 percent. ...
... designed specifically to enable direct inspection of ... for pediatric applications as well. Its insertion ... 2.8mm across. As a result, insertion into ... greater ease. And since this sophisticated scope ...
Indications For Usage: , Thoracic surgery. , Broncho-spirometry. , Thoracoscopies. , Differential or selective lung ventilation. , Lung Lavage. ...
... double lumen tube made of silicone rubber with ... to the characteristics of silicone rubber, Silbronco is ... insertion. Furthermore, the tube will not soften like ... term surgery., ,Silbronco is also especially useful ...
Medicine Products: